ENTX Receives FDA Feedback
Entera Bio receives FDA's positive feedback for its Phase 3 registrational protocol for EB613 tablet to treat osteoporosis
Reported Earlier: Entera Bio Receives FDA's Positive Feedback For Its Phase 3 Registrational Protocol For EB613 Tablet In Development To Treat Osteoporosis